Jonathan M. N. Rigby
Independent DirectorMr. Jonathan M. N. Rigby, M.B.A., is Director of ReAlta Life Sciences, Inc. since January 2026. He has been Chief Executive Officer & President of Sernova Biotherapeutics Inc (formerly known as Sernova Corp.) since August 2024 and had been its Interim Chairman from June 02, 2025 and had been its Executive Chairman since July 15, 2024 until 2025 and serves as its Director since May 28, 2024. He is Chairman and Chief Business Officer of BioPlus Acquisition Corp. He is Independent Director of Oncolytics Biotech Inc since August 30, 2022. He served as Group Chief Executive Officer of Revolo Biotherapeutics Limited until January 2024. He serves as President, Group Chief Executive Officer and Director of Revolo Biotherapeutics Inc. (formerly Immune Regulation Ltd. and Inc.). He served as Director at Thermalin Diabetes, LLC since August 2020 until May 2021. He also served on the board of directors of Thermalin, Inc. from May 2020 to July 2021. He has been a Director of ImmunoMolecular Therapeutics, Inc. since January 2021. He served as Chairman of CollPlant Biotechnologies. From 2011 to 2018, he was the Chief Executive Officer and President at SteadyMed Therapeutics, Inc. He was the Chairman of the Board at CollPlant Holdings Ltd. since February 4, 2019 until August 6, 2019 and was its Director since February 4, 2019 until August 23, 2019. In 2011, he founded SteadyMed Therapeutics Inc. He has been the Chief Executive Officer and President at SteadyMed Ltd. since August 2011. He was Independent Non-Executive Board Member of Xeris Pharmaceuticals, Inc. until May 08, 2019. Based in the U.S., he has a successful track record of growing and capitalizing specialty pharmaceutical companies. He led SteadyMed through its IPO in 2015 and subsequent sale to United Therapeutics in August 2018. He served as Vice President of Business Development at Zogenix, Inc. from May 2006 to December 2011. In 2006, he co-founded Zogenix Inc and was instrumental in its growth and subsequent Initial Public Offering (IPO). He has pharmaceutical, biotech and drug delivery industry experience. He served as Vice President of Business Development of Aradigm Corporation from 2002 to August 2006 where he led the original acquisition and subsequent strategic development of Intraject assets. At Aradigm, he was responsible for the strategic acquisition of the Intraject technology in 2003. He joined Aradigm in 2002. He served as Head of Corporate Development at Aradigm Corporation. In 2006, he Co-led the management buy out of the DosePro assets from Aradigm Corporation and the associated venture financing of it. From 1995 to 2002, he served as the Head of Business Development, Head of Business Intelligence and Head of UK Sales for Profile Therapeutics UK. In his career, he held various sales, marketing & managerial positions in cardiovascular and respiratory pharmaceuticals with Bristol Myers Squibb and Merck. He serves as Vice Chairman of the Association of Needle Free Injection Manufacturers. He served as a Director at SteadyMed Ltd. from August 2011 to August 30, 2018. He served as a Director of SteadyMed Therapeutics, Inc. He worked at Phillips Medical. He is a frequent speaker at industry conferences in the drug delivery sector. He earned his Bachelor of Science Degree in Biological Sciences with Honors from Sheffield University, UK. He also holds a first class advanced degree in Applied Biology and an MBA from Portsmouth University, UK. He also holds a British Technology Higher National Diploma in Applied Biology from Sheffield University, UK.
Positions
- Company NameOncolytics Biotech Inc.Stock CodeONCYPositionIndependent DirectorColleagues
- JKJared KellyCEO & Director
- WFWayne F. PisanoChairman of the Board
- KJKirk J. LookChief Financial Officer
- TCThomas C. HeinemanChief Medical Officer
- JMJohn McAdoryChief Operating Officer
- AHAllison HagermanChief Technology Officer
- AFAngela Frances HolthamIndependent Director
- DMDeborah M. BrownIndependent Director
- JMJonathan M. N. RigbyIndependent Director
- Company NameSernova Biotherapeutics IncStock CodeSEOVFPositionPresident, CEO & DirectorColleagues
- JLJohn L. BrooksIndependent Chairman
- JTJames T. ParsonsChief Financial Officer
- MRMarylyn RigbyChief Communications Officer
- DBDavid BurkeVice President of Investor Relations
- PBPatricia BeastonSernova Biotherapeutics Inc.
- RARobert A. GabbayChairman of Clinical Advisory Board
- NCNorman C. W. WongMember of Scientific Advisory Board
- JDJannette DufourMember of Scientific Advisory Board
